Zenas BioPharma Prices $200 Million Convertible Notes Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 27 2026
0mins
Source: Newsfilter
- Funding Size: Zenas BioPharma announced a public offering of 5 million shares at $20.00 each and $200 million in 2.50% convertible senior notes, with estimated net proceeds of approximately $287.5 million, significantly strengthening the company's capital base for future growth.
- Bond Terms: The convertible notes will mature in 2032 with a 2.50% interest rate and allow conversion under specific conditions, featuring an initial conversion price of about $26.50 per share, representing a 32.5% conversion premium, enhancing investor appeal.
- Use of Proceeds: Zenas intends to utilize the proceeds to support the U.S. commercial launch of obexelimab and advance orelabrutinib clinical trials, demonstrating confidence in its product pipeline and responsiveness to market demand.
- Underwriter Lineup: Jefferies, Evercore ISI, Citigroup, and Guggenheim Securities are acting as joint book-running managers for the offerings, indicating strong market trust in Zenas and recognition of its future growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZBIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZBIO
Wall Street analysts forecast ZBIO stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 18.580
Low
19.00
Averages
41.20
High
55.00
Current: 18.580
Low
19.00
Averages
41.20
High
55.00
About ZBIO
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on development and commercialization of therapies for patients living with autoimmune diseases. It is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, its lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcgRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. Orelabrutinib is a highly selective central nervous system (CNS)-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib's mechanism of action targets pathogenic B cells not only in periphery but also within CNS. Its earlier stage programs include ZB021, an oral small molecule IL-17AA/AF inhibitor; ZB022, a preclinical, oral, brain-penetrant, TYK2 inhibitor, and ZB014, a preclinical, half-life extended anti-CD19 and FcgRIIb monoclonal antibody.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zenas BioPharma to Present at Neuro Perspectives Summit
- Management Presentation: Zenas BioPharma will present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit on June 15, 2026, with the presentation available on-demand starting at 7:00 a.m. ET, showcasing the company's latest advancements in autoimmune disease therapies.
- Core Business Strategy: Zenas BioPharma is committed to identifying, acquiring, and developing product candidates that can provide clinical benefits for patients with autoimmune diseases, leveraging an experienced leadership team and a disciplined acquisition approach to establish its presence in the biopharmaceutical sector.
- Key Product Candidates: The company is advancing two late-stage potential franchise molecules, obexelimab, a bifunctional monoclonal antibody designed to inhibit pathogenic B cell activity, and orelabrutinib, a highly selective oral BTK inhibitor that penetrates the CNS, addressing inflammation and disease progression in multiple sclerosis.
- Early Stage Program Development: Zenas is also developing early-stage candidates such as ZB021, ZB022, and ZB014, which are positioned to potentially offer best-in-class clinical outcomes, further solidifying the company's research and development capabilities in the autoimmune disease treatment landscape.
See More
Zenas BioPharma's INDIGO Study Achieves Key Milestones
- Significant Study Results: Zenas BioPharma's INDIGO study successfully met its primary and all key secondary endpoints, with obexelimab significantly reducing glucocorticoid usage and related toxicities, marking a major advancement in treating IgG4-related disease.
- Clinical Data Support: During the 52-week randomized controlled period, patients treated with obexelimab experienced a 56% reduction in the risk of IgG4-RD flares (HR 0.44), with 73.2% remaining flare-free, demonstrating its long-term efficacy and safety.
- Good Safety and Tolerability: The safety profile of obexelimab was comparable to placebo, with treatment-emergent adverse events occurring in 97.9% of patients and a lower incidence of serious adverse events at 11.3%, indicating its favorable tolerability in clinical applications.
- Future Development Prospects: Zenas plans to report topline results for systemic lupus erythematosus in Q4 2026, further advancing the clinical development of obexelimab and showcasing its broad potential in autoimmune disease treatment.
See More
Zenas BioPharma Submits BLA for Obexelimab in IgG4-RD
- Clinical Trial Success: Zenas BioPharma's INDIGO trial demonstrated a 56% reduction in IgG4-RD flare risk with obexelimab, achieving high statistical significance (p=0.0005), establishing a strong foundation for its role as a first-line therapy in long-term management.
- Regulatory Milestone: The submission of the Biologics License Application (BLA) to the FDA for obexelimab marks a significant advancement in the treatment of autoimmune diseases, potentially providing new options for patients and enhancing market competitiveness.
- Robust Clinical Data Support: Obexelimab has been evaluated in eight clinical trials involving 383 subjects, showing good tolerability and clinical activity, which strengthens its potential as a treatment for IgG4-RD and may drive future market acceptance.
- Future Development Plans: Zenas expects to report results from its systemic lupus erythematosus trial in Q4 2026, indicating a continued commitment to investment and research in autoimmune diseases, which could open new growth opportunities for the company.
See More
Zenas BioPharma Presents Phase 3 INDIGO Trial Results
- Significant Trial Results: Zenas BioPharma's INDIGO trial demonstrated a 56% significant reduction in the risk of IgG4-related disease flare with obexelimab (HR 0.443, p=0.0005), not only meeting the primary endpoint but also providing strong clinical justification for future treatment options.
- Good Safety Profile: The trial reported treatment-emergent adverse events in 97.9% of obexelimab participants compared to 95.9% in the placebo group, with a significantly lower incidence of Grade ≥3 adverse events (11.3% vs 23.7%), indicating its favorable tolerability.
- Multiple Secondary Endpoints Achieved: Obexelimab showed high statistical significance across all four key secondary endpoints, including time to first flare (p=0.0001) and complete remission rates (p=0.0049), establishing a solid foundation for its competitive positioning in the market.
- Positive Future Outlook: Zenas plans to report results from its systemic lupus erythematosus trial in Q4 2026, further validating obexelimab's clinical application potential, which is expected to enhance the company's market position in autoimmune diseases.
See More
Zenas BioPharma Q1 Earnings Beat Expectations
- Strong Earnings Report: Zenas BioPharma reported a Q1 GAAP EPS of -$1.46, beating expectations by $0.22, indicating improvements in financial management that may boost investor confidence.
- Healthy Cash Position: As of March 31, 2026, the company had $718.5 million in cash, cash equivalents, and investments, along with $45 million from the underwriters' full exercise of their over-allotment option, ensuring liquidity for upcoming years.
- Future Funding Assurance: The company anticipates receiving a potential $75 million milestone from Royalty Pharma and $75 million drawn from Pharmakon's debt facility, which will further support its operating expenses and capital expenditures at least through Q2 2029, enhancing market confidence in its long-term growth.
- Optimistic Market Outlook: Zenas BioPharma is rated as a 'Strong Buy' on the enhancement of obexelimab and expected SLE data in Q4 2026, reflecting strong market anticipation for its products, which could drive stock price increases.
See More
Zenas BioPharma CEO Purchases Over $1M in Shares
- Insider Buying: Zenas BioPharma CEO Lonnie Moulder disclosed in a regulatory filing that he purchased 60,000 shares at an average price of $17.79, totaling over $1M, indicating strong confidence in the company's future.
- Increased Stake: Following these transactions, Moulder's stake in Zenas has risen to nearly 1.8M shares, reflecting his firm belief in the company's long-term growth, especially in light of upcoming mid-stage trial data.
- Ongoing Investment: From January to March, Moulder added nearly $3.7M worth of company stock in three separate transactions, each exceeding $1M, demonstrating his bullish outlook on the company's prospects.
- Market Anticipation: Zenas BioPharma is awaiting mid-stage trial data for its lead asset obexelimab targeting systemic lupus erythematosus, a pivotal moment that could significantly impact the company's market performance and stock price trajectory.
See More
Zenas BioPharma to Present at Neuro Perspectives Summit
- Management Presentation: Zenas BioPharma will present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit on June 15, 2026, with the presentation available on-demand starting at 7:00 a.m. ET, showcasing the company's latest advancements in autoimmune disease therapies.
- Core Business Strategy: Zenas BioPharma is committed to identifying, acquiring, and developing product candidates that can provide clinical benefits for patients with autoimmune diseases, leveraging an experienced leadership team and a disciplined acquisition approach to establish its presence in the biopharmaceutical sector.
- Key Product Candidates: The company is advancing two late-stage potential franchise molecules, obexelimab, a bifunctional monoclonal antibody designed to inhibit pathogenic B cell activity, and orelabrutinib, a highly selective oral BTK inhibitor that penetrates the CNS, addressing inflammation and disease progression in multiple sclerosis.
- Early Stage Program Development: Zenas is also developing early-stage candidates such as ZB021, ZB022, and ZB014, which are positioned to potentially offer best-in-class clinical outcomes, further solidifying the company's research and development capabilities in the autoimmune disease treatment landscape.
See More
Zenas BioPharma's INDIGO Study Achieves Key Milestones
- Significant Study Results: Zenas BioPharma's INDIGO study successfully met its primary and all key secondary endpoints, with obexelimab significantly reducing glucocorticoid usage and related toxicities, marking a major advancement in treating IgG4-related disease.
- Clinical Data Support: During the 52-week randomized controlled period, patients treated with obexelimab experienced a 56% reduction in the risk of IgG4-RD flares (HR 0.44), with 73.2% remaining flare-free, demonstrating its long-term efficacy and safety.
- Good Safety and Tolerability: The safety profile of obexelimab was comparable to placebo, with treatment-emergent adverse events occurring in 97.9% of patients and a lower incidence of serious adverse events at 11.3%, indicating its favorable tolerability in clinical applications.
- Future Development Prospects: Zenas plans to report topline results for systemic lupus erythematosus in Q4 2026, further advancing the clinical development of obexelimab and showcasing its broad potential in autoimmune disease treatment.
See More
Zenas BioPharma Submits BLA for Obexelimab in IgG4-RD
- Clinical Trial Success: Zenas BioPharma's INDIGO trial demonstrated a 56% reduction in IgG4-RD flare risk with obexelimab, achieving high statistical significance (p=0.0005), establishing a strong foundation for its role as a first-line therapy in long-term management.
- Regulatory Milestone: The submission of the Biologics License Application (BLA) to the FDA for obexelimab marks a significant advancement in the treatment of autoimmune diseases, potentially providing new options for patients and enhancing market competitiveness.
- Robust Clinical Data Support: Obexelimab has been evaluated in eight clinical trials involving 383 subjects, showing good tolerability and clinical activity, which strengthens its potential as a treatment for IgG4-RD and may drive future market acceptance.
- Future Development Plans: Zenas expects to report results from its systemic lupus erythematosus trial in Q4 2026, indicating a continued commitment to investment and research in autoimmune diseases, which could open new growth opportunities for the company.
See More
Zenas BioPharma Presents Phase 3 INDIGO Trial Results
- Significant Trial Results: Zenas BioPharma's INDIGO trial demonstrated a 56% significant reduction in the risk of IgG4-related disease flare with obexelimab (HR 0.443, p=0.0005), not only meeting the primary endpoint but also providing strong clinical justification for future treatment options.
- Good Safety Profile: The trial reported treatment-emergent adverse events in 97.9% of obexelimab participants compared to 95.9% in the placebo group, with a significantly lower incidence of Grade ≥3 adverse events (11.3% vs 23.7%), indicating its favorable tolerability.
- Multiple Secondary Endpoints Achieved: Obexelimab showed high statistical significance across all four key secondary endpoints, including time to first flare (p=0.0001) and complete remission rates (p=0.0049), establishing a solid foundation for its competitive positioning in the market.
- Positive Future Outlook: Zenas plans to report results from its systemic lupus erythematosus trial in Q4 2026, further validating obexelimab's clinical application potential, which is expected to enhance the company's market position in autoimmune diseases.
See More
Zenas BioPharma Q1 Earnings Beat Expectations
- Strong Earnings Report: Zenas BioPharma reported a Q1 GAAP EPS of -$1.46, beating expectations by $0.22, indicating improvements in financial management that may boost investor confidence.
- Healthy Cash Position: As of March 31, 2026, the company had $718.5 million in cash, cash equivalents, and investments, along with $45 million from the underwriters' full exercise of their over-allotment option, ensuring liquidity for upcoming years.
- Future Funding Assurance: The company anticipates receiving a potential $75 million milestone from Royalty Pharma and $75 million drawn from Pharmakon's debt facility, which will further support its operating expenses and capital expenditures at least through Q2 2029, enhancing market confidence in its long-term growth.
- Optimistic Market Outlook: Zenas BioPharma is rated as a 'Strong Buy' on the enhancement of obexelimab and expected SLE data in Q4 2026, reflecting strong market anticipation for its products, which could drive stock price increases.
See More
Zenas BioPharma CEO Purchases Over $1M in Shares
- Insider Buying: Zenas BioPharma CEO Lonnie Moulder disclosed in a regulatory filing that he purchased 60,000 shares at an average price of $17.79, totaling over $1M, indicating strong confidence in the company's future.
- Increased Stake: Following these transactions, Moulder's stake in Zenas has risen to nearly 1.8M shares, reflecting his firm belief in the company's long-term growth, especially in light of upcoming mid-stage trial data.
- Ongoing Investment: From January to March, Moulder added nearly $3.7M worth of company stock in three separate transactions, each exceeding $1M, demonstrating his bullish outlook on the company's prospects.
- Market Anticipation: Zenas BioPharma is awaiting mid-stage trial data for its lead asset obexelimab targeting systemic lupus erythematosus, a pivotal moment that could significantly impact the company's market performance and stock price trajectory.
See More
